Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)

作者：Icli Fikri^*; Akbulut Hakan; Onur Handan; Yalcin Bulent; Demirkazik Ahmet; Senler Filiz Cay

来源：Breast, 2011, 20(2): 155-157.

DOI：10.1016/j.breast.2010.09.002

• Breast cancer
• Adjuvant treatment
• Cisplatin
• Etoposide
• Docetaxel

Background and objectives: Previous reports suggest that including cisplatin plus etoposide in the adjuvant treatment may improve the outcomes in patients with early breast cancer.
Patients and Methods: Forty-one patients with early breast cancer and 4 or more positive lymph nodes were treated with 3 cycles of EoP (oral etoposide plus cisplatin) in addition to 3 cycles of AC (doxorubicin plus cyclophosphamide) and 3 cycles of T (docetaxel) (Group 1). Toxicity and survival results were compared to those with similar disease characteristics who were treated with 4 cycles of AC plus 4 cycles of T (Group 2) during the same period.
Results: There were no long-term side effects related to EoP. While median disease-free and overall survivals were not reached in Group 1, they were 107 +/- 13 (p = 0.387) months and 123 +/- 5 months (p = 0.618) in Group 2. Likewise 10-year disease-free survivals (DFS) were 59.3% and 44.7% respectively.
Conclusions: The trend towards improvement in survival with adjuvant AC + T + EoP when compared to AC + T needs to be studied in randomized trial.

• 出版日期2011-4